Compare CORT & GTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CORT | GTLB |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 5.5B |
| IPO Year | 2001 | 2021 |
| Metric | CORT | GTLB |
|---|---|---|
| Price | $110.60 | $43.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 27 |
| Target Price | ★ $96.50 | $37.17 |
| AVG Volume (30 Days) | 1.3M | ★ 4.1M |
| Earning Date | 04-30-2026 | 06-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | $761,407,000.00 | ★ $955,224,000.00 |
| Revenue This Year | $26.08 | $18.72 |
| Revenue Next Year | $26.98 | $16.05 |
| P/E Ratio | $1,246.44 | ★ N/A |
| Revenue Growth | 12.79 | ★ 25.81 |
| 52 Week Low | $28.66 | $18.73 |
| 52 Week High | $122.21 | $52.38 |
| Indicator | CORT | GTLB |
|---|---|---|
| Relative Strength Index (RSI) | 62.28 | 74.18 |
| Support Level | $76.41 | $36.50 |
| Resistance Level | $122.21 | $47.35 |
| Average True Range (ATR) | 5.00 | 1.99 |
| MACD | -0.03 | 0.78 |
| Stochastic Oscillator | 65.76 | 99.48 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
GitLab Inc operates on an all-remote model. GitLab is a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation, following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, & the Asia Pacific. It focused on accelerating innovation & broadening the distribution of its platform to companies across the world.